<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03322761</url>
  </required_header>
  <id_info>
    <org_study_id>Morten_Riemenschneider_PhD</org_study_id>
    <nct_id>NCT03322761</nct_id>
  </id_info>
  <brief_title>Early Exercise Efforts in Multiple Sclerosis</brief_title>
  <official_title>Exercise as a Supplemental Treatment Strategy Early in the Disease Course of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to investigate whether early exercise efforts can expand the use of exercise
      in Multiple sclerosis (MS), from symptom treatment only, to early supplementary
      disease-modifying treatment.

      The study will be conducted in a randomized and controlled manner, with single blinding.
      Participants will be allocated to either a systematic aerobic exercise intervention or an
      educational programme on exercise and physical activity. Both interventions will last 1 year,
      and involve a 1 year follow-up period.

      It is hypothesized that early exercise efforts can modify the disease activity and disability
      progression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple Sclerosis (MS) is an autoimmune and neurodegenerative disease in the central nervous
      system (CNS), characterized by a complex pathogenesis and heterogeneous symptoms. The
      histopathological hallmark of the disease is sclerotic lesions. These inflammatory lesions
      manifests as disabling relapses, and the number of relapses in the first few years after
      disease onset is associated with progression of disability, with a higher number of relapses
      leading to a more rapid progression. In addition, diffuse neurodegeneration seems to occur
      early in the disease, and even though it is not always clinically evident it is associated
      with disease progression. A reduction in relapse rate and neurodegeneration early in the MS
      disease course may slow the progression of disabilities and can possibly reduce overall
      disease burden. For the individual person with MS (pwMS) a reduction in overall disease
      burden will often improve quality of life, and since MS is a lifelong disease this is of
      great interest. Preventing disability in pwMS is also highly relevant in a societal
      perspective, as it lowers the large costs associated with increased disability. As a
      consequence, the importance of early treatment have been emphasized.

      Treatment of MS have seen great advances in the recent years, resulting in an increasing
      number of available disease-modifying treatments (DMT). Despite the fact that the current
      DMTs favourable alter a number of clinical outcomes and the course of the disease, it is
      still a serious and deteriorating condition with significant disease activity, impaired
      neurological functions and thus progression of disabilities. New and supplemental treatment
      strategies are therefore still warranted, and exercise have gained attention as a safe and
      tolerable rehabilitation strategy. Recently, exercise furthermore have gained substantial
      attention, as the first indications of neuroprotective and disease-modifying effects of
      exercise has been published. However, despite the focus on early treatment in medical DMTs no
      studies have investigated the effects of exercise as a supplemental treatment strategy early
      in the disease course of MS.

      Consequently, the purpose of this study is to investigate the effects of early exercise
      efforts on disease activity and disability progression. In a sub-group the effects will
      furthermore be investigated on brain volume, specific brain regions, and inflammation.

      It is hypothesized that early exercise efforts can modify the disease activity and disability
      progression, by reducing the relapse rate, the progression of Multiple Sclerosis Functional
      Composite (MSFC) and Expanded Disability Status Scale (EDSS) scores. The rate of brain
      atrophy and the lesion load, obtained by MRI scans, is also hypothesized to be reduced. This
      is expected to be due to an exercise-induced reduction in inflammation.

      The study will be a randomised and controlled study with randomisation to either an
      systematic aerobic exercise intervention or an educational programme on exercise and physical
      activity. Both interventions are in addition to standard treatment, and will last 1 year. The
      exercise intervention will consist of 2 supervised exercise sessions per week in the complete
      duration of the study, while the standard treatment plus exercise education program will
      consist of 4 educational sessions on the health benefits associated with exercise and
      physical activity held every third month throughout the intervention period. The training in
      the exercise group will be aerobic exercise (running, cycling, rowing or on a cross-trainer)
      planned by exercise physiologists and performed in a progressive manner. To allow handling of
      a large number of participants, who is also geographically spread, the exercise intervention
      will be locally anchored, but at the same time supervised by student employees from Section
      for Sports Science and controlled by internet- and telephonic communication. In addition to
      the two intervention groups, data from The Danish MS registry will serve as population based
      standard treatment control data. All groups will be followed up 1 year after cessation of the
      interventions.

      To set the estimated number of participants a two-sample two-sided power calculation has been
      conducted. The basis for this calculation is an report from Tallner et al. who have shown a
      difference in relapse rate during a two-year period (equal to our 1 year intervention, and 1
      year follow-up) of 0.65 relapses between physically active and physically inactive MS
      patients (active: 0.95 +/- 0.97 relapses in 2 years ; inactive: 1.60 +/- 1.64 relapses in 2
      years). 83 patients with MS should be enrolled in each intervention group (a 20% drop-out
      rate has been included). Newly published data on the brain atrophy in percentage of total
      brain volume after 24 weeks of resistance training have been the basis for a similar
      calculation of the number of participants in the sub-group, from whom MRI-scans and blood
      samples will be obtained. 41 participants from each intervention group should form this
      sub-group.

      MS is a complex disease with heterogenous symptoms, and by combining the disciplines of
      exercise physiology, neurology and radiology this study can be the first long-term and
      large-scale exercise study to investigate the possible neuroprotective and disease-modifying
      effects of exercise when initiated early in the disease course of MS. Consequently, this
      project has the potential to change present clinical practice and generate further attention
      to exercise, not only as symptom treatment, but also as an supplemental disease-modifying
      treatment strategy early in the course of MS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Annual Relapse Rate (ARR)</measure>
    <time_frame>ARR, 1 year intervention; 1 year follow up.</time_frame>
    <description>Number of relapses, registered and validated by neurologist, on annual basis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage brain volume change</measure>
    <time_frame>Baseline, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Brain atrophy will be measured from MRI-scans</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Composite score from Timed 25-Feet Walk Test (T25FWT), 9-Hole Peg Test (9HPT), Paced Auditory Serial Addition Test (PASAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS) score</measure>
    <time_frame>Baseline, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Disability status score assessed and registered by neurologist. The scale ranges from 0-10 in 0.5 unit increments representing higher levels of disability.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Functional capacity, Six-minute walk test (6MWT)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Distance covered during a six-minute maximal walking test</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional capacity, Six-spot-step-test (SSST)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>SSSt is a measure of walking ability, balance and coordination. Measured as the time to complete the six-spot course.</description>
  </other_outcome>
  <other_outcome>
    <measure>Functional capacity, Accelerometry</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Measurement of level of physical activity by wearing a accelerometer for 7 days at each timepoint. Measured in counts/min.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cognition, Symbol Digit Modality Test (SDMT)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Assessment of cognitive function, with a higher number of correct answers in the test representing better cognitive function.</description>
  </other_outcome>
  <other_outcome>
    <measure>Short Form Health Survey 36 (SF-36)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing health status. The SF-36 consists of eight subscales, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multiple Sclerosis Impact Scale 29 (MSIS-29)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing the impact of the disease. 20 questions measure the physical impact, and 9 questions measure the psychological impact. Each question is scored from 1-5. A greater score is equal to a larger impact.</description>
  </other_outcome>
  <other_outcome>
    <measure>Multiple Sclerosis Walking Scale 12 (MSWS-12)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing the impact of the disease on walking. Each question is scored from 1-5 and then summed and transformed to a 0-100 scale. Higher scores indicate a greater impact on walking.</description>
  </other_outcome>
  <other_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>Baseline, 24 weeks, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Questionnaire assessing the effects of fatigue on physical, cognitive and psychosocial functioning. The score of the MFIS is the sum of the scores for the 21 items. A higher score represents a higher impact of fatigue, in general or in relation to one of the above mentioned areas.</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammation</measure>
    <time_frame>Baseline, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Blood samples will be analyzed for key inflammatory cytokines</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of lesions</measure>
    <time_frame>Baseline, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Number of lesions, measured by MRI-scanning.</description>
  </other_outcome>
  <other_outcome>
    <measure>Lesion load</measure>
    <time_frame>Baseline, after 1 year intervention, and again at 1 year follow up.</time_frame>
    <description>Volume of lesions, measured by MRI-scanning.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Systematic exercise training</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two weekly supervised aerobic exercise trainings for 48 weeks. The training will be planned by exercise physiologists, and performed in a progressive manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Educational program</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Educational program on physical activity and health, consisting of four educational sessions in the intervention period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment alone</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Data from The Danish MS Registry will serve as control-data for standard treatment alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Systematic exercise training</intervention_name>
    <description>Combination of standard medical treatment and systematic early exercise training in persons with MS.</description>
    <arm_group_label>Systematic exercise training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Educational program</intervention_name>
    <description>Informations regarding health benefits of physical activity and exercise.</description>
    <arm_group_label>Educational program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed consent

          -  Definite diagnosis with Relapsing remitting multiple sclerosis (RRMS)

          -  No more than 2 years since diagnosis

          -  Expectedly able to carry out high intensity aerobic training

          -  Able to transport themselves to and from training sessions

        Exclusion Criteria:

          -  Pregnancy

          -  Dementia, alcohol abuse, or pacemaker

          -  Metallic implants, hindering MRI-scans

          -  Comorbidities hindering participation in high intensity aerobic training
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morten Riemenschneider, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section for Sport Science, Department of Public Health, Aarhus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morten Riemenschneider, MSc</last_name>
    <phone>+4522855185</phone>
    <email>mori@ph.au.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrik Dalgas, PhD</last_name>
    <phone>+4540123039</phone>
    <email>dalgas@ph.au.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Section for Sport Science, Department of Public Health, University of Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Riemenschneider, M.Sc.</last_name>
      <phone>+4522855185</phone>
      <email>mori@ph.au.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ulrik Dalgas, PhD.</last_name>
      <phone>+4540123039</phone>
      <email>dalgas@ph.au.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Compston A, Coles A. Multiple sclerosis. Lancet. 2008 Oct 25;372(9648):1502-17. doi: 10.1016/S0140-6736(08)61620-7.</citation>
    <PMID>18970977</PMID>
  </reference>
  <reference>
    <citation>Ziemssen T, De Stefano N, Sormani MP, Van Wijmeersch B, Wiendl H, Kieseier BC. Optimizing therapy early in multiple sclerosis: An evidence-based view. Mult Scler Relat Disord. 2015 Sep;4(5):460-469. doi: 10.1016/j.msard.2015.07.007. Epub 2015 Jul 17. Review.</citation>
    <PMID>26346796</PMID>
  </reference>
  <reference>
    <citation>Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler. 2005 Apr;11(2):232-9. Review.</citation>
    <PMID>15794399</PMID>
  </reference>
  <reference>
    <citation>Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.</citation>
    <PMID>24485135</PMID>
  </reference>
  <reference>
    <citation>Elovaara I. Early treatment in multiple sclerosis. J Neurol Sci. 2011 Dec;311 Suppl 1:S24-8.</citation>
    <PMID>22206762</PMID>
  </reference>
  <reference>
    <citation>Dalgas U, Stenager E, Ingemann-Hansen T. Multiple sclerosis and physical exercise: recommendations for the application of resistance-, endurance- and combined training. Mult Scler. 2008 Jan;14(1):35-53. Epub 2007 Sep 19. Review.</citation>
    <PMID>17881393</PMID>
  </reference>
  <reference>
    <citation>Kj√∏lhede T, Siemonsen S, Wenzel D, Stellmann JP, Ringgaard S, Pedersen BG, Stenager E, Petersen T, Vissing K, Heesen C, Dalgas U. Can resistance training impact MRI outcomes in relapsing-remitting multiple sclerosis? Mult Scler. 2017 Jul 1:1352458517722645. doi: 10.1177/1352458517722645. [Epub ahead of print]</citation>
    <PMID>28752800</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2017</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple sclerosis</keyword>
  <keyword>Exercise</keyword>
  <keyword>Disease-modifying treatment</keyword>
  <keyword>Early treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

